Aridis Pharmaceuticals (ARDS) stock Forecast for 2022 – 2026
Last update: November 26, 2022 (17:07)Sector: Healthcare
The share price of Aridis Pharmaceuticals, Inc. (ARDS) now
What analysts predict: $12
52-week high/low: $2.99 / $0.68
50/200 Day Moving Average: $1.054 / $1.424
This figure corresponds to the average price over the previous 50/200 days. For Aridis Pharmaceuticals stocks, the 50-day moving average is the resistance level today.
For Aridis Pharmaceuticals stocks, the 200-day moving average is the resistance level today.
Are you interested in Aridis Pharmaceuticals, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Aridis Pharmaceuticals stock price in 2022, 2023, 2024, 2025, 2026. How much will one Aridis Pharmaceuticals share be worth in 2022 - 2026?
When should I take profit in Aridis Pharmaceuticals stock? When should I record a loss on Aridis Pharmaceuticals stock? What are analysts' forecasts for Aridis Pharmaceuticals stock? What is the future of Aridis Pharmaceuticals stock? We forecast Aridis Pharmaceuticals stock performance using neural networks based on historical data on Aridis Pharmaceuticals stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Aridis Pharmaceuticals stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Aridis Pharmaceuticals shares. This happens once a day.
Historical and forecast chart of Aridis Pharmaceuticals stock
The chart below shows the historical price of Aridis Pharmaceuticals stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Aridis Pharmaceuticals stock price can be found in the table below.
Long-term forecasts by years.
Aridis Pharmaceuticals daily forecast for a month
Aridis Pharmaceuticals Daily Price Targets
Aridis Pharmaceuticals Stock Forecast 11-28-2022.
Forecast target price for 11-28-2022: $0.90.
Positive dynamics for Aridis Pharmaceuticals shares will prevail with possible volatility of 3.264%.
Pessimistic target level: 0.89
Optimistic target level: 0.92
Aridis Pharmaceuticals Stock Forecast 11-29-2022.
Forecast target price for 11-29-2022: $0.91.
Positive dynamics for Aridis Pharmaceuticals shares will prevail with possible volatility of 3.520%.
Pessimistic target level: 0.90
Optimistic target level: 0.93
Aridis Pharmaceuticals Stock Forecast 11-30-2022.
Forecast target price for 11-30-2022: $0.89.
Negative dynamics for Aridis Pharmaceuticals shares will prevail with possible volatility of 4.408%.
Pessimistic target level: 0.87
Optimistic target level: 0.91
Aridis Pharmaceuticals Stock Forecast 12-01-2022.
Forecast target price for 12-01-2022: $0.90.
Positive dynamics for Aridis Pharmaceuticals shares will prevail with possible volatility of 2.913%.
Pessimistic target level: 0.89
Optimistic target level: 0.91
Aridis Pharmaceuticals Stock Forecast 12-02-2022.
Forecast target price for 12-02-2022: $0.92.
Positive dynamics for Aridis Pharmaceuticals shares will prevail with possible volatility of 4.084%.
Pessimistic target level: 0.91
Optimistic target level: 0.94
Aridis Pharmaceuticals Stock Forecast 12-03-2022.
Forecast target price for 12-03-2022: $0.94.
Positive dynamics for Aridis Pharmaceuticals shares will prevail with possible volatility of 2.021%.
Pessimistic target level: 0.93
Optimistic target level: 0.95
ARDS (ARDS) Monthly Stock Prediction for 2022
Aridis Pharmaceuticals forecast for this year
Aridis Pharmaceuticals Stock Prediction for Dec 2022
An uptrend is forecast for this month with an optimal target price of $0.900736. Pessimistic: $0.79. Optimistic: $0.98
Aridis Pharmaceuticals (ARDS) Monthly Stock Prediction for 2023
Aridis Pharmaceuticals (ARDS) Monthly Stock Prediction for 2024
Aridis Pharmaceuticals (ARDS) Monthly Stock Prediction for 2025
Aridis Pharmaceuticals (ARDS) Monthly Stock Prediction for 2026
Aridis Pharmaceuticals information and performance
Aridis Pharmaceuticals, Inc. Is a biopharmaceutical company specializing in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAbs) to treat infections. MABs represent a treatment approach that allows the human immune system to fight infections and is designed to overcome the disadvantages associated with current therapies, such as increased drug resistance, short response times, negative effects on the human microbiome, and lack of differentiation between treatment alternatives. Its product pipeline includes human MABs that target specific pathogens associated with bacterial infections, most notably hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). Its leading candidate product, AR-301, targets the alpha toxin produced by the gram-positive bacteria Staphylococcus aureus, a common pathogen associated with HAP and VAP. Its AR-101 (Aerumab) is a fully human immunoglobulin M targeting P. aeruginosa serotype O11.
5941 OPTICAL COURT, SAN JOSE, CA, US
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.